Mounjaro vs Ozempic®
Side-by-side comparison of Mounjaro and Ozempic® — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Mounjaro | Ozempic® |
|---|
| Generic name | Mounjaro | Ozempic® |
|---|
| Sponsor | Nicholas Skertich | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
|---|
| Drug class | — | GLP-1 receptor agonist |
|---|
| Molecular target | Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor | GLP-1R (glucagon-like peptide-1 receptor) |
|---|
| Modality | Small molecule | Small molecule |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Metabolic | Diabetes |
|---|
Mechanism of action
| Mounjaro | — |
|---|
| Ozempic® | Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes. |
|---|
Approved indications
Ozempic®
- Type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease
Common side effects
Mounjaro
- Gastrointestinal adverse reactions (15 mg)
- Gastrointestinal adverse reactions (10 mg)
- Gastrointestinal adverse reactions (5 mg)
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
Ozempic®
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Further reading